Newly emerging viruses, such as severe acute respiratory syndrome coronavirus (SARS-CoV), Middle Eastern respiratory syndrome CoVs (MERS-CoV), and H7N9, cause fatal acute lung injury (ALI) by driving hypercytokinemia and aggressive inflammation through mechanisms that remain elusive. In SARS-CoV/macaque models, we determined that anti–spike IgG (S-IgG), in productively infected lungs, causes severe ALI by skewing inflammation-resolving response. Alveolar macrophages underwent functional polarization in acutely infected macaques, demonstrating simultaneously both proinflammatory and wound-healing characteristics. The presence of S-IgG prior to viral clearance, however, abrogated wound-healing responses and promoted MCP1 and IL-8 production and proinflammatory monocyte/macrophage recruitment and accumulation. Critically, patients who eventually died of SARS (hereafter referred to as deceased patients) displayed similarly accumulated pulmonary proinflammatory, absence of wound-healing macrophages, and faster neutralizing antibody responses. Their sera enhanced SARS-CoV–induced MCP1 and IL-8 production by human monocyte–derived wound-healing macrophages, whereas blockade of FcγR reduced such effects. Our findings reveal a mechanism responsible for virus-mediated ALI, define a pathological consequence of viral specific antibody response, and provide a potential target for treatment of SARS-CoV or other virus-mediated lung injury.
Li Liu, Qiang Wei, Qingqing Lin, Jun Fang, Haibo Wang, Hauyee Kwok, Hangying Tang, Kenji Nishiura, Jie Peng, Zhiwu Tan, Tongjin Wu, Ka-Wai Cheung, Kwok-Hung Chan, Xavier Alvarez, Chuan Qin, Andrew Lackner, Stanley Perlman, Kwok-Yung Yuen, Zhiwei Chen
Title and authors | Publication | Year |
---|---|---|
A receptor-binding domain-based nanoparticle vaccine elicits durable neutralizing antibodies against SARS-CoV-2 and variants of concern
I-Jung Lee, Yu-Hua Lan, Ping-Yi Wu, Yan-Wei Wu, Yu-Hung Chen, Sheng-Che Tseng, Tzu- Kuo, Cheng-Pu Sun, Jia-Tsrong Jan, Hsiu-Hua Ma, Chun-Che Liao, Jian-Jong Liang, Hui- Ko, Chih-Shin Chang, Wen-Chun Liu, Yi-An Ko, Yen-Hui Chen, Zong-Lin Sie, Szu-I Tsung, Yi-Ling Lin, I-Hsuan Wang, Mi-Hua Tao |
Emerging Microbes & Infections | 2023 |
Structural insights into broadly neutralizing antibodies elicited by hybrid immunity against SARS-CoV-2.
Luo M, Zhou B, Reddem ER, Tang B, Chen B, Zhou R, Liu H, Liu L, Katsamba PS, Au KK, Man HO, To KK, Yuen KY, Shapiro L, Dang S, Ho DD, Chen Z |
Emerging Microbes & Infections | 2023 |
Coagulopathy and the humoral response against viral proteins in patients at different stages of COVID-19
Monteiro FP, Tavares VD, Souza RD, Venâncio LP, Fabres-Klein MH, do Carmo RF, Klein RC, Lima JB, Araújo-Santos T |
Memórias do Instituto Oswaldo Cruz | 2023 |
Immunity in SARS-CoV-2 Infection: Clarity or Mystery? A Broader Perspective in the Third Year of a Worldwide Pandemic
Kapten K, Orczyk K, Smolewska E |
Archivum Immunologiae et Therapiae Experimentalis | 2023 |
Integrative network pharmacology and in silico analyses identify the anti-omicron SARS-CoV-2 potential of eugenol
Liu Y |
Heliyon | 2023 |
Exploring the Role of Immune System and Inflammatory Cytokines in SARS-CoV-2 Induced Lung Disease: A Narrative Review
Tirelli C, De Amici M, Albrici C, Mira S, Nalesso G, Re B, Corsico AG, Mondoni M, Centanni S |
Biology | 2023 |
Novel ACE2 fusion protein with adapting activity against SARS-CoV-2 variants in vitro
Zekri L, Ruetalo N, Christie M, Walker C, Manz T, Rammensee HG, Salih HR, Schindler M, Jung G |
Frontiers in immunology | 2023 |
A linear SARS-CoV-2 DNA vaccine candidate reduces virus shedding in ferrets.
Martins M, do Nascimento GM, Conforti A, Noll JCG, Impellizeri JA, Sanchez E, Wagner B, Lione L, Salvatori E, Pinto E, Compagnone M, Viscount B, Hayward J, Shorrock C, Aurisicchio L, Diel DG |
Archives of Virology | 2023 |
Review of therapeutic mechanisms and applications based on SARS-CoV-2 neutralizing antibodies
Liu M, Gan H, Liang Z, Liu L, Liu Q, Mai Y, Chen H, Lei B, Yu S, Chen H, Zheng P, Sun B |
Frontiers in microbiology | 2023 |
In vitro immunogenic profile of recombinant SARS-CoV2 S1-RBD peptide in murine macrophage and microglial cells
Chaves AJ Filho, Jucá PM, Soares MV, de Oliveira CA, de Sousa RC, Lós DB, Russo RC, Yaochite JN, Macedo DS |
Memórias do Instituto Oswaldo Cruz | 2023 |
SARS-CoV-2 infection and immune responses
Harne R, Williams B, Abdelal HF, Baldwin SL, Coler RN |
AIMS Microbiology | 2023 |
Non-neutralizing antibodies to SARS-Cov-2-related linear epitopes induce psychotic-like behavior in mice
Xu J, Wei H, You P, Sui J, Xiu J, Zhu W, Xu Q |
Frontiers in molecular neuroscience | 2023 |
Immunology of SARS-CoV-2 infection and vaccination
Lin B, Cheng L, Zhang J, Yang M, Zhang Y, Liu J, Qin X |
Clinica chimica acta; international journal of clinical chemistry | 2023 |
Innate and adaptive immunity to SARS-CoV-2 and predisposing factors
Shen J, Fan J, Zhao Y, Jiang D, Niu Z, Zhang Z, Cao G |
Frontiers in immunology | 2023 |
Safety, tolerability, pharmacokinetics, and immunogenicity of an anti-SARS-CoV-2 monoclonal antibody HFB30132A after single dose intravenous administration in healthy Chinese subjects: a phase 1, randomized, double-blind, placebo-controlled study
Li S, Wu X, Li N, Cao G, Wang J, Chen Y, Li S, He J, Wu J, Yang H, Lin K, Qiu C, Liu A, Zhou H, Adrian F, Schweizer L, Zhang W, Gu J, Zhang J |
Frontiers in pharmacology | 2023 |
Enhancement of SARS-CoV-2 N Antigen-Specific T Cell Functionality by Modulating the Autophagy-Mediated Signal Pathway in Mice
Wen Z, Yuan Y, Zhao Y, Wang H, Han Z, Li M, Yuan J, Sun C |
Viruses | 2023 |
Antibodies Capable of Enhancing SARS-CoV-2 Infection Can Circulate in Patients with Severe COVID-19
Matveev A, Pyankov O, Khlusevich Y, Tyazhelkova O, Emelyanova L, Timofeeva A, Shipovalov A, Chechushkov A, Zaitseva N, Kudrov G, Yusubalieva G, Yussubaliyeva S, Zhukova O, Baklaushev V, Sedykh S, Lifshits G, Tikunov A, Tikunova N |
International journal of molecular sciences | 2023 |
LSDV-Vectored SARS-CoV-2 S and N Vaccine Protects against Severe Clinical Disease in Hamsters
de Moor WR, Williamson AL, Schäfer G, Douglass N, Gers S, Sutherland AD, Blumenthal MJ, Margolin E, Shaw ML, Preiser W, Chapman R |
Viruses | 2023 |
Antibody-Dependent Enhancement with a Focus on SARS-CoV-2 and Anti-Glycan Antibodies
Ziganshina MM, Shilova NV, Khalturina EO, Dolgushina NV, V. Borisevich S, Yarotskaya EL, Bovin NV, Sukhikh GT |
Viruses | 2023 |
SARS-CoV-2 hijacks neutralizing dimeric IgA for nasal infection and injury in Syrian hamsters1
Zhou B, Zhou R, Chan JF, Zeng J, Zhang Q, Yuan S, Liu L, Robinot R, Shan S, Liu N, Ge J, Kwong HY, Zhou D, Xu H, Chan CC, Poon VK, Chu H, Yue M, Kwan KY, Chan CY, Chan CC, Chik KK, Du Z, Au KK, Huang H, Man HO, Cao J, Li C, Wang Z, Zhou J, Song Y, Yeung ML, To KK, Ho DD, Chakrabarti LA, Wang X, Zhang L, Yuen KY, Chen Z |
Emerging Microbes & Infections | 2023 |
Refinement of an ovine-based immunoglobulin therapy against SARS-CoV-2, with comparison of whole IgG versus F(ab')(2) fragments.
Findlay-Wilson S, Easterbrook L, Smith S, Pope N, Aldridge M, Humphries G, Schuhmann H, Ngabo D, Rayner E, Otter A, Coleman T, Hicks B, Halkerston R, Apostolakis K, Taylor S, Fotheringham S, Horton A, CanoCejas I, Wand M, Tree JA, Sutton M, Graham V, Hewson R, Dowall S |
Scientific Reports | 2023 |
Identification of new drugs to counteract anti-spike IgG-induced hyperinflammation in severe COVID-19
Geyer CE, Chen HJ, Bye AP, Manz XD, Guerra D, Caniels TG, Bijl TP, Griffith GR, Hoepel W, de Taeye SW, Veth J, Vlaar AP, Vidarsson G, Bogaard HJ, Aman J, Gibbins JM, van Gils MJ, de Winther MP, den Dunnen J |
Life science alliance | 2023 |
Variant-dependent oxidative and cytokine responses of human neutrophils to SARS-CoV-2 spike protein and anti-spike IgG1 antibodies
Almeida NB, Fantone KM, Sarr D, Ashtiwi NM, Channell S, Grenfell RF, Martins-Filho OA, Rada B |
Frontiers in immunology | 2023 |
An inhaled bioadhesive hydrogel to shield non-human primates from SARS-CoV-2 infection
Mei X, Li J, Wang Z, Zhu D, Huang K, Hu S, Popowski KD, Cheng K |
Nature Materials | 2023 |
Independent Protection and Influence of the Spike-Specific Antibody Response of SARS-CoV-2 Nucleocapsid Protein (N) in Whole-Virion Vaccines
Yang H, Xie Y, Lu S, Sun Y, Wang K, Li S, Wang J, Liao G, Li C |
Human vaccines | 2023 |
Development of AAV-delivered broadly neutralizing anti-human ACE2 antibodies against SARS-CoV-2 variants
Sun CP, Chiu CW, Wu PY, Tsung SI, Lee IJ, Hu CW, Hsu MF, Kuo TJ, Lan YH, Chen LY, Ng HY, Chung MJ, Liao HN, Tseng SC, Lo CH, Chen YJ, Liao CC, Chang CS, Liang JJ, Draczkowski P, Puri S, Chang YC, Huang JS, Chen CC, Kau JH, Chen YH, Liu WC, Wu HC, Danny Hsu ST, Wang IH, Tao MH |
Molecular Therapy | 2023 |
PD-L1 expression levels in mesenchymal stromal cells predict their therapeutic values for autoimmune hepatitis
Bai X, Chen T, Li Y, Ge X, Qiu C, Gou H, Wei S, Liu T, Yang W, Yang L, Liang Y, Jia Z, Lv L, Li T |
Stem Cell Research & Therapy | 2023 |
SARS-CoV-2 nucleocapsid protein, rather than spike protein, triggers a cytokine storm originating from lung epithelial cells in patients with COVID-19.
Wang YC, Tsai CH, Wang YC, Yen LC, Chang YW, Sun JR, Lin TY, Chiu CH, Chao YC, Chang FY |
Infection | 2023 |
The Therapeutic Monoclonal Antibody Bamlanivimab Does Not Enhance SARS-CoV-2 Infection by FcR-Mediated Mechanisms.
Cross RW, Wiethoff CM, Brown-Augsburger P, Berens S, Blackbourne J, Liu L, Wu X, Tetreault J, Dodd C, Sina R, Witcher DR, Newcomb D, Frost D, Wilcox A, Borisevich V, Agans KN, Woolsey C, Prasad AN, Deer DJ, Geisbert JB, Dobias NS, Fenton KA, Strifler B, Ebert P, Higgs R, Beall A, Chanda S, Riva L, Yin X, Geisbert TW |
2023 |